corporate_fare

VectorY Therapeutics B.V.

Address
Science Park 408

Sponsor Overview

assignment
1
sponsored trial
science
2
molecules
location_city
4
research centres
public
3
countries
person_search
3
investigators

Specializations

Amyotrophic Lateral Sclerosis

VectorY Therapeutics B.V. is engaged in clinical research focused on amyotrophic lateral sclerosis, with activity centered on therapies intended for motor neuron disease and related neurodegenerative mechanisms.

  • Neurodegeneration
  • Motor neuron disease
  • Neuromuscular function

The sponsor’s current clinical portfolio reflects interest in therapeutic development for progressive neurological conditions affecting movement, strength, and functional decline.

Central Nervous System Therapeutics

Its research activity also aligns with central nervous system treatment development, with attention to interventions designed for disorders involving neuronal loss and impaired neuromuscular signaling.

  • Neurological disorders
  • Therapeutic neurology
  • Neuronal preservation

Clinical work in this area points to a medical focus on conditions where preserving neural integrity is a key therapeutic objective.

Safety and Tolerability Evaluation

VectorY Therapeutics B.V. is involved in clinical assessment of safety and tolerability in people living with neurological disease, supporting the development of candidate treatments for serious unmet needs.

  • Clinical safety
  • Tolerability assessment
  • Patient monitoring

This area reflects a therapeutic emphasis on establishing the clinical suitability of new approaches in a vulnerable patient population.

Neuromuscular Disease Innovation

The sponsor’s clinical interests extend to innovative approaches for neuromuscular disease, particularly conditions characterized by progressive weakness and loss of motor control.

  • Motor function
  • Functional impairment
  • Disease-modifying therapy

Its research landscape is shaped by work in advanced therapeutic strategies for severe neurological illness.

Sponsored Trials

Trial Name Country Status
Phase 1/2 Study to Evaluate the Safety and Tolerability of VTx-002 in Patients with Amyotrophic Lateral SclerosisBelgium BelgiumSpain SpainThe Netherlands The NetherlandsRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 4 sites collaborated multiple times

This sponsor has worked with 4 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Nervous System Diseases1 trial
    449 other sponsors

Partnered Research Centres

4 centres
location_city
assignment364
Bellvitge University Hospital
Address
Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
Learn morearrow_forward
location_city
assignment922
Hospital Universitario Y Politecnico La Fe
Address
Avenida Fernando Abril Martorell 106, 46026 Valencia
Learn morearrow_forward
location_city
assignment1165
Katholieke Universiteit te Leuven
Address
Herestraat 49, 3000 Leuven
Learn morearrow_forward
location_city
assignment477
Universitair Medisch Centrum Utrecht
Address
Heidelberglaan 100, 3584 CX Utrecht
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to VectorY Therapeutics B.V..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.